CJC + Ipamorelin
CJC-1295 no DAC + Ipamorelin: GHRH and Ghrelin-Receptor Research
CJC-1295 no DAC and Ipamorelin are different peptides connected to growth-hormone-axis research through separate receptor mechanisms.
Two receptor routes
CJC-1295 no DAC is a modified growth-hormone-releasing hormone analog. Ipamorelin is a growth-hormone secretagogue peptide associated with ghrelin-receptor research.
Both compounds relate to the growth-hormone axis, but they do not enter the system through the same receptor route. CJC-1295 no DAC belongs to the GHRH analog category, while Ipamorelin is discussed through growth-hormone secretagogue receptor signaling.
Research-use only: the material is supplied for laboratory research, not for human or veterinary administration.
What no DAC means
The no DAC phrase refers to the absence of the drug-affinity-complex modification. In analog design, such modifications can alter binding properties, molecular persistence and how researchers compare related compounds.
CJC-1295 no DAC is therefore a specific naming convention, not just a generic CJC label. Exact naming matters because CJC analogs can differ in structure and research behavior.
Ipamorelin as a secretagogue peptide
Ipamorelin is a pentapeptide. It is frequently discussed as a selective growth-hormone secretagogue in relation to the ghrelin receptor, also known as GHSR-1a.
The combination of CJC-1295 no DAC and Ipamorelin is commonly supplied as lyophilized research material. The material contains two separate peptide identities connected by endocrine signaling research, not one single compound.
Research-use boundary
Unauthorized human-use risk context
This section is a safety boundary, not application guidance. The material is not supplied for human or veterinary administration, and the points below do not describe expected effects or acceptable use.
- Research-use material has not been supplied as a finished pharmaceutical product, so unauthorized human use can involve unknown identity, impurity, sterility, immune-response and contamination risks.
- Combining GHRH-analog and secretagogue research contexts can increase uncertainty around endocrine feedback, receptor signaling and compound interaction.
- Because this compound is discussed around endocrine-axis signaling, unauthorized human use could theoretically disturb hormone-related feedback systems, fluid balance, glucose handling, sleep, appetite or other regulated processes.
- If a non-sterile or improperly characterized material were introduced into the body, possible risks include infection, inflammatory reactions, fever-like responses, local tissue irritation and other serious adverse events.
